About Foghorn Therapeutics Inc.
https://foghorntx.comFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
CEO
Adrian H. B. Gottschalk
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FLAGSHIP PIONEERING INC.
Shares:12.67M
Value:$79.97M
FMR LLC
Shares:5.47M
Value:$34.54M
BVF INC/IL
Shares:5.3M
Value:$33.46M
Summary
Showing Top 3 of 93
About Foghorn Therapeutics Inc.
https://foghorntx.comFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $8.15M ▲ | $6.65M ▼ | $-15.85M ▲ | -194.39% ▲ | $-0.25 ▲ | $-15M ▲ |
| Q2-2025 | $7.56M ▲ | $27.75M ▼ | $-17.94M ▲ | -237.34% ▲ | $-0.28 ▲ | $-17.04M ▲ |
| Q1-2025 | $5.95M ▲ | $28.86M ▲ | $-18.83M ▲ | -316.43% ▲ | $-0.3 ▲ | $-22.09M ▲ |
| Q4-2024 | $2.86M ▼ | $26.86M ▼ | $-19.5M ▼ | -682.88% ▼ | $-0.31 | $-23.24M ▼ |
| Q3-2024 | $7.81M | $31.66M | $-19.12M | -244.9% | $-0.31 | $-23.12M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $180.28M ▼ | $204.96M ▼ | $294.62M ▼ | $-89.66M ▼ |
| Q2-2025 | $198.66M ▼ | $226.24M ▼ | $302.89M ▼ | $-76.66M ▼ |
| Q1-2025 | $220.59M ▼ | $258.69M ▼ | $320.34M ▼ | $-61.65M ▼ |
| Q4-2024 | $243.75M ▼ | $283.98M ▼ | $329.51M ▼ | $-45.53M ▼ |
| Q3-2024 | $267.4M | $308.37M | $336.66M | $-28.29M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-15.85M ▲ | $-18.86M ▲ | $35.57M ▲ | $49K ▼ | $16.76M ▲ | $-18.86M ▲ |
| Q2-2025 | $-17.94M ▲ | $-21M ▲ | $33.83M ▲ | $254K ▲ | $12.8M ▲ | $-21.02M ▲ |
| Q1-2025 | $-18.83M ▲ | $-23.97M ▲ | $29.4M ▲ | $139K ▲ | $5.57M ▲ | $-24M ▲ |
| Q4-2024 | $-19.5M ▼ | $-24.52M ▼ | $22.29M ▲ | $4K ▼ | $-2.22M ▲ | $-25M ▼ |
| Q3-2024 | $-19.12M | $-21M | $-61.31M | $1.05M | $-81.27M | $-21.31M |
CEO
Adrian H. B. Gottschalk
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FLAGSHIP PIONEERING INC.
Shares:12.67M
Value:$79.97M
FMR LLC
Shares:5.47M
Value:$34.54M
BVF INC/IL
Shares:5.3M
Value:$33.46M
Summary
Showing Top 3 of 93